is an immunosuppressant commonly used to prevent organ rejection but is associated with hyperlipidemia and an increased risk of cardiovascular disease. Although studies suggest that CsA-induced hyperlipidemia is mediated by inhibition of low-density lipoprotein receptor (LDLr)-mediated lipoprotein clearance, the data supporting this are inconclusive. We therefore sought to investigate the role of the LDLr in CsA-induced hyperlipidemia by using Ldlr-knockout mice (Ldlr −/− ). Approach and Results-Ldlr −/− and wild-type (wt) C57Bl/6 mice were treated with 20 mg/kg per d CsA for 4 weeks. On a chow diet, CsA caused marked dyslipidemia in Ldlr −/− but not in wt mice. Hyperlipidemia was characterized by a prominent increase in plasma very low-density lipoprotein and intermediate-density lipoprotein/LDL with unchanged plasma high-density lipoprotein levels, thus mimicking the dyslipidemic profile observed in humans. Analysis of specific lipid species by liquid chromatography-tandem mass spectrometry suggested a predominant effect of CsA on increased very low-density lipoprotein-IDL/LDL lipoprotein number rather than composition. Mechanistic studies indicated that CsA did not alter hepatic lipoprotein production but did inhibit plasma clearance and hepatic uptake of [ 14 C]cholesteryl oleate and glycerol tri[ 3 H]oleate-double-labeled very low-density lipoprotein-like particles. Further studies showed that CsA inhibited plasma lipoprotein lipase activity and increased levels of apolipoprotein C-III and proprotein convertase subtilisin/kexin type 9. Conclusions-We demonstrate that CsA does not cause hyperlipidemia via direct effects on the LDLr. Rather, LDLr deficiency plays an important permissive role for CsA-induced hyperlipidemia, which is associated with abnormal lipoprotein clearance, decreased lipoprotein lipase activity, and increased levels of apolipoprotein C-III and proprotein convertase subtilisin/kexin type 9. Enhancing LDLr and lipoprotein lipase activity and decreasing apolipoprotein C-III and proprotein convertase subtilisin/kexin type 9 levels may therefore provide attractive treatment targets for patients with hyperlipidemia receiving CsA. The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
H yperlipidemia is observed in 40% to 60% of organ transplant recipients and has been linked to the use of immunosuppressant agents such as corticosteroids, sirolimus, and cyclosporine A (CsA). [1] [2] [3] Transplant hyperlipidemia is characterized by high plasma cholesterol and triglyceride levels. 2 Specifically, CsA increases very low-density lipoprotein (VLDL) and low-density lipoprotein (LDL) concentrations and shows variable effects on plasma high-density lipoprotein. Although multiple factors potentially contribute to hyperlipidemia in patients, such as post-transplantation obesity, multiple drug therapy, and diabetes mellitus, CsA monotherapy can independently lead to elevated plasma triglyceride and cholesterol levels in humans which are reversible on cessation of immunosuppression therapy. 4 The immunosuppressive effect of CsA is mediated by inhibition of protein phosphatase 2B (calcineurin) and subsequent activation of the transcription factor nuclear factor of transcription. The mechanism(s) by which CsA leads to hyperlipidemia are most likely not related to nuclear factor of transcription inhibition 1, 4 as tacrolimus (FK506), another nuclear factor of transcription-inhibiting immunosuppressant, does not induce hyperlipidemia. 3 Animal and cell studies have indicated that CsA may affect many aspects of lipid metabolism. 1 In 1996, Rayyes 5 and Winegard 6 suggested that CsA increased plasma LDL and VLDL levels via decreased low-density lipoprotein receptor (LDLr) activity. The precise role of the LDLr in mediating CsA-mediated hypercholesterolemia, however, is unclear. Cell culture studies identified that CsA can inhibit β-VLDL uptake via the LDLr in the human hepatoma HepG2 cell line. 6 CsA was also found to reduce LDLr-mediated binding and uptake of LDL in HepG2 cells, and this was associated with a reduction in hepatic LDLr mRNA levels. 5 However, in vivo studies did not corroborate these findings. Hepatic LDLr protein levels decreased in mice treated with CsA 7 but were unaffected in rats 8 even though both models demonstrated CsA-induced hyperlipidemia. These studies suggest that CsAmediated hyperlipidemia may be related to effects on targets other than the LDLr, such as activation of hepatic cholesterol synthesis or inhibition of lipoprotein lipolysis. In vivo studies in rats demonstrated that CsA reduced LDL production and catabolism, 9 while in renal transplant recipients reduced catabolism of chylomicron-like emulsion particles, and a reduced fractional catabolic rate of VLDL has been observed. 10, 11 Given the current and increasing clinical importance of contemporary therapies such as statins and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in promoting LDLr-mediated lipoprotein uptake, we sought to investigate the role of the LDLr in CsA-induced hyperlipidemia by studying Ldlr-knockout mice. We report that CsA induces hyperlipidemia in chow-fed Ldlr −/− mice but not in wild-type (wt) C57Bl/6 mice, indicating that LDLr deficiency has an indirect role in the development of CsAinduced hyperlipidemia. We further show that CsA inhibits lipoprotein clearance in the Ldlr −/− mouse and modulates plasma apolipoprotein C-III (apoC-III) levels, lipoprotein lipase (LPL) activity, and PCSK9 levels, suggesting a complex interaction among CsA, LDLr, and lipoprotein metabolism in vivo.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

CsA Treatment
Mice were administered 20 mg/kg per d CsA or vehicle (control) via osmotic minipumps. This CsA dose has previously been shown to reduce transplant rejection in mice while not inducing liver and kidney toxicity. 12, 13 Whole-blood CsA levels were 1087±124 ng/mL and 711±91 ng/mL after 1 week and 4 weeks, respectively, consistent with levels reported by others using a similar delivery method. 14 Mouse weights were not affected (23.3±0.3 versus 23.2±0.3 g, for control and CsA, respectively). Histological examination of liver and kidney sections revealed no signs of toxicity after CsA treatment ( Figure I in the online-only Data Supplement).
It is known that Ldlr −/− mice have increased hepatic lipid content compared with C57Bl/6 wild-type (wt) mice and are more vulnerable to develop nonalcoholic steatohepatitis after high-fat feeding, although they do not develop fatty livers on a chow diet. 15 This was supported by our histological studies ( Figure I in the online-only Data Supplement). Hepatic cholesterol, cholesteryl ester (CE), and triglyceride contents were higher in Ldlr −/− mice compared with wt mice, most marked in triglyceride content (115 versus 30 nmol/mg; P<0.05; Table 1 ). In the wt mice, CsA treatment increased hepatic CE content from 11 to 20 nmol/mg (P<0.01) without significantly increasing other lipids. In Ldlr −/− mice, CsA caused no significant changes in hepatic lipid content.
CsA Treatment Increases Plasma Lipid Levels in Ldlr −/− Mice but not in wt Mice
CsA treatment did not affect plasma total cholesterol or triglyceride levels in wt mice ( Figure 1A and 1B). However, in Ldlr −/− mice fed a chow diet, CsA markedly elevated total plasma cholesterol (263±12 versus 527±31 mg/dL, control versus CsA, respectively; P<0.0001) and triglyceride levels (156±13 versus 253±19 mg/dL in control versus CsA, respectively; P<0.001; Figure 1C and 1D). The increase in plasma lipid levels was paralleled by an increase in plasma apoB100, apoB48, and apoE levels, whereas no differences in plasma apoA-I were observed ( Figure 1E ). Analysis of plasma lipoprotein fractions by fast protein liquid chromatography established that wt mice had a prominent high-density lipoprotein peak and barely detectable VLDL/intermediate-density lipoprotein (IDL)/LDL fractions (Figure 2A and 2B), and this lipoprotein profile did not change after CsA treatment. In contrast, Ldlr −/− mice treated with vehicle had prominent VLDL, IDL/ LDL-cholesterol, and VLDL-triglyceride levels that were markedly higher after administration of CsA, increasing 1.9-fold, 4.2-fold, and 2.5-fold for VLDL-triglyceride, VLDL-cholesterol, and IDL/LDL-cholesterol, respectively ( Figure 2C and 2D).
Insulin tolerance tests demonstrated a similarly rapid initial decline in blood glucose levels within 15 minutes of insulin administration in both control and CsA-treated mice ( Figure IIA in the online-only Data Supplement). Blood glucose levels, however, remained lower in the CsA-treated mice at 60 minutes, suggesting increased rather than decreased insulin sensitivity with CsA, which was supported by quantification of the glucose area under the curve ( Figure IIB in the online-only Data Supplement). These data indicate that although CsA-treated mice exhibit marked hyperlipidemia, they are not insulin resistant. 
Lipidomics of Plasma and Lipoprotein Fractions
To investigate if the changes in lipid levels were related to changes in particle number or qualitative changes in particle composition, detailed lipidomic analysis of whole plasma and lipopoprotein fractions was undertaken using liquid chromatography-tandem mass spectrometry. Confirming our data from Figure 2 , plasma cholesterol, CE, and triglyceride levels were all significantly elevated after CsA treatment ( Table 2 ). In addition, significant increases in plasma levels of diacylglycerol and phosphatidylcholine were observed. Analysis of VLDL, IDL/LDL, and high-density lipoprotein revealed that although total levels of VLDL and IDL/LDL were elevated in plasma ( Figure 2 ), CsA treatment did not affect the amount of cholesterol, CE, or triglyceride per unit of phosphatidylcholine (Table 2) or per unit of apoB (Table II in the online-only Data Supplement), indicating that the cholesterol, CE, or triglyceride content per lipoprotein particle was largely unaffected. Taken together, these results suggest that CsA increases VLDL-IDL/LDL particle numbers rather than affecting particle composition. Analysis of minor lipid classes detected by liquid chromatography-tandem mass spectrometry indicated that although most lipid species within VLDL or IDL/LDL were unchanged after CsA treatment, sphingomyelin (SM) decreased relative to phosphatidylcholine within VLDL and IDL/LDL fractions (Table 3) , whereas LPC and PI increased in VLDL only. These were not significantly different relative to apoB ( Table III in the online-only Data Supplement). Further examination of SM species identified differences in response to CsA according to acyl chain length and saturation ( Taken together, these results suggest that the predominant effect of CsA is to increase plasma VLDL and IDL/LDL particle number rather than lipoprotein particle composition.
CsA Does Not Affect Hepatic VLDL Synthesis or Secretion
As the lipidomic analysis suggested that CsA treatment increases VLDL-IDL/LDL particle number, we investigated whether CsA increases hepatic VLDL production and secretion. CsA significantly increased hepatic mRNA levels of several genes involved in lipid metabolism, specifically Sterol regulatory element-binding transcription factor 1 and its target genes fatty acid synthase and Stearoyl-coA desaturase-1 ( Figure 3A ). 3-Hydroxy-3-methyl-glutaryl-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, and PCSK9 were also increased but did not reach significance (P=0.06). None of these mRNA species were upregulated by CsA in wt mice ( Figure III in the online-only Data Supplement). Although CsA increased hepatic mRNA levels of fatty acid synthase and stearoyl-coA desaturase-1 in Ldlr −/− mice, it had no effect on their respective hepatic protein levels ( Figure 3B ). In addition, protein levels of microsomal triglyceride transfer protein, the protein responsible for VLDL assembly, were also unaffected by CsA treatment ( Figure 3B ).
Because an effect of CsA on microsomal triglyceride transfer protein activity could not be excluded, in vivo hepatic triglyceride secretion rates were determined after injection of Triton WR1339 to block lipolysis. Triglyceride secretion rates were unaffected after CsA (4.2±0.6 mg/min for control versus 3.8±0.5 mg/min for control versus CsA, respectively; Figure 3C ). To obtain rates of secretion of newly synthesized apoB, [ 35 S]-methionine was injected before blocking lipolysis. The rate of secretion of newly synthesized VLDL-[ 35 S]apoB ( Figure 3D ) did not differ significantly (P=0.21) between control and CsA-treated mice. In addition, the VLDL-triglyceride/ [ 35 S]apoB ratio ( Figure 3E ) in these experiments was unaffected by CsA (P=0. 26 ), suggesting unchanged composition in the newly synthesized particles. Taken together, these results indicate that CsA-induced hyperlipidemia is not explained by an increase in hepatic VLDL production or secretion.
CsA Inhibits Plasma Lipoprotein Lipase Activity and Clearance of VLDL-Like Particles
CsA has been reported to decrease plasma LPL activity in humans and in rats, 16, 17 which may partly explain increased plasma VLDL and IDL/LDL levels. We therefore determined LPL activity after CsA treatment in both Ldlr −/− and wt mice. CsA did not affect LPL activity in wt mice ( Figure 4A) ; however, LPL activity was significantly lower in CsA-treated Ldlr −/− mice (352±71 versus 185±17 mU/mL for control and CsA, respectively; P<0.05; Figure 4B ). To determine whether decreased LPL activity affected VLDL particle size, VLDL was isolated by density ultracentrifugation, and particle size was analyzed using dynamic light scattering. VLDL particle size was 73.0±14.5 nm in control and 75.8±11.4 nm in CsAtreated mice, suggesting that CsA treatment did not affect particle size ( Figure IV in the online-only Data Supplement).
ApoC-III is an important endogenous inhibitor of LPL activity, and previous reports have observed increased apoC-III levels in transplant recipients treated with CsA. 18, 19 Western blot analysis indicated that CsA increased plasma apoC-III levels in Ldlr −/− mice but did not in wt mice ( Figure 4C and  4D) . These results support the possibility that in Ldlr −/− mice, CsA-induced hyperlipidemia is at least in part related to inhibition of LPL activity, which may be mediated by increased apoC-III levels.
To determine whether CsA attenuated the clearance of lipoproteins, the effect of CsA on in vivo clearance of tri[ 3 H] oleate (triolein, TO)-and [ 14 C]cholesteryl oleate (CO)-doublelabeled VLDL-like particles was investigated. Previous studies have indicated that these particles show comparable plasma kinetics and tissue uptake activity as endogenous triglyceriderich lipoproteins. 20 Ldlr −/− mice showed delayed clearance and decreased hepatic uptake of particle-derived [ 14 C]CO compared with wt mice ( Figure 5 ; Figure V in the online-only Data Supplement), which is in line with previous reports. 21 CsA did not affect plasma clearance of [ 3 H]TO or [ 14 C]CO in wt mice ( Figure 5A and 5B) ; however, it significantly decreased clearance of [ 3 H]TO (P<0.0001) and [ 14 C]CO (P<0.0001) in Ldlr −/− mice ( Figure 5C and 5D ). In the presence of CsA, the plasma half-life of TO was increased from 4.2 to 7.6 minutes (P<0.001) and of CO from 3.7 to 7.6 minutes (P<0.001).
Tissue accumulation of [ 3 H] and [ 14 C] was also assessed. CsA significantly reduced tissue uptake of [ 3 H]TO-derived [ 3 H]oleate in the heart ( Figure 5F ) but not in other tissues in Ldlr −/− mice. Importantly, CsA decreased total accumulation of lipoprotein-derived [ 14 C]CO ( Figure 5H ) into the liver by 32±4% (P<0.05) supporting inhibition of particle clearance by the liver. In summary, these results indicate that CsA-induced hyperlipidemia in the Ldlr −/− mouse is most likely mediated by decreased plasma clearance of lipoproteins.
CsA Increases Plasma PCSK9 Levels in Ldlr −/−
PCSK9 has been recently identified as a major contributor to LDL clearance, especially via the LDLr, and is itself elevated under conditions of Ldlr −/− deficiency. 22 Importantly, it remains possible that PCSK9 has effects on lipoprotein metabolism additional to its effects on the LDLr expression. 23 We therefore investigated whether CsA affected PCSK9 levels in Ldlr −/− mice. We were unable to detect PCSK9 in plasma from wt mice, with or without CsA exposure ( Figure VI in the online-only Data Supplement). In contrast, there was abundant PCSK9 in Ldlr −/− mice, and this increased after exposure to CsA ( Figure 6A) , with a strong correlation between blood CsA and PCSK9 levels in these mice ( Figure 6B ). There was also a strong correlation between LDL-cholesterol and PCSK9 levels in Ldlr −/− mice treated with CsA ( Figure 6C ), whereas plasma PCSK9 only weakly correlated with LDL-cholesterol in vehicle-treated mice ( Figure 6D ), suggesting CsA concurrently acts via an LDLr-independent pathway to elevate PCSK9 and LDL-cholesterol in Ldlr −/− mice. Other receptors involved in lipoprotein clearance, some of which have been identified as PCSK9 targets, 24, 25 were investigated. CsA treatment did not affect hepatic levels of low-density lipoprotein receptorrelated protein 1 or syndecan-1 nor levels of apoE receptor 2 or VLDL receptor in brain or heart, respectively ( Figure 6E-6H ).
Discussion
We have demonstrated that CsA-induced dyslipidemia does not require inhibition of the LDLr and does not require the presence of a high-fat Western diet. Our studies identify a complex interaction among CsA, lipoprotein clearance pathways, and the LDLr such that LDLr deficiency seems to be permissive for CsA-induced hyperlipidemia. Treatment with CsA markedly increases plasma cholesterol and triglyceride levels in chow-fed Ldlr −/− , mice and this is associated with a marked increase in plasma VLDL and IDL/LDL levels, decreased lipolysis, hepatic lipoprotein clearance, and increased plasma PCSK9 levels.
The first key finding of our study was that CsA induced a marked hyperlipidemia in the Ldlr −/− mice. Thus, although previous cellular studies suggested that CsA may modulate LDLr activity levels in HepG2 cells, 5, 6 direct inhibition of LDLr activity by CsA is clearly not essential for the development of hyperlipidemia. The second important observation is that we did not observe dyslipidemia in wt mice with functional LDLr fed a chow diet and exposed to CsA. This most likely indicates that LDLr-mediated lipoprotein clearance plays a protective role against CsA-mediated hyperlipidemia.
Many insights into the role of lipoprotein receptors have arisen from animal models completely deficient in these receptors, even though complete deficiency is rare in humans (eg, apoE −/− , LDLr −/− , and SRB1 −/− ). On this basis, our results in Ldlr −/− mice establish a proof of principle that the LDLr has an important role in determining whether CsA causes hyperlipidemia. In addition, our findings also imply that lower LDLrmediated clearance activity, as observed in heterozygous familial hypercholesterolemia, may promote CsA-mediated hyperlipidemia and that enhanced LDLr-mediated clearance after exposure to statins and PCSK9 inhibitors, may mitigate against the effects of CsA.
CsA markedly increased plasma VLDL and IDL/LDL levels, whereas it did not affect plasma high-density lipoprotein levels, in agreement with observations of human CsA-induced hyperlipidemia. 2 Because elevated VLDL is typical of insulin resistance, we investigated whether the hyperlipidemia in CsA-treated Ldlr −/− mice was associated with insulin resistance. We found that CsA-treated mice were not insulin resistant but instead seemed to demonstrate improved insulin sensitivity. Improved insulin sensitivity in response to CsA has been reported recently in obese high-fat-fed C57Bl/6 mice. 26 However, caution must be exercised in applying these findings to clinical studies as immunosuppressive drugs such as CsA increase the risk of developing diabetes mellitus, most likely via effects on insulin secretion. 27 Analysis of individual lipid species in VLDL and IDL/ LDL fractions indicated that although absolute levels of lipid species in plasma were increased, lipid composition per particle (per phosphatidylcholine or apoB) did not change for the vast majority of lipid species. These data suggest that the predominant effect of CsA was to increase plasma lipoprotein particle number without substantially affecting particle composition. The 1 lipid species that did change in both VLDL and IDL/LDL was SM, which was decreased by 16% and 7% for VLDL and IDL/LDL, respectively (Tables 2 and 3; Tables  II and III in the online-only Data Supplement). Decreased SM content of LDL can be associated with increased LDL aggregation and binding to proteoglycans, but this depends on the action of sphingomyelinase and the concomitant accumulation of ceramides. 28 Because the ceramide content of lipoproteins in this study was not affected by CsA, it is unclear whether the small decrease in SM content would have any physiological consequences.
The increase in VLDL and IDL/LDL caused by CsA seems to be mediated by effects on clearance rather than hepatic production or synthesis. CsA did not significantly increase the levels of proteins important in lipoprotein synthesis. In addition, VLDL secretion was directly measured and found to be unchanged by CsA. In contrast, CsA inhibited plasma clearance and hepatic uptake of VLDL-like particles containing both [ 3 H]TO and [ 14 C]CO in Ldlr −/− mice, indicating that CsA-induced hyperlipidemia in a LDLr-deficient environment is primarily a function of decreased hepatic clearance. We identified at least 3 candidate mechanisms by which this occurs. Plasma LPL activity was inhibited, and this was associated with a concomitant increase in its inhibitory cofactor apoC-III. Effects on lipases and apoC-III after CsA treatment have been observed in humans as well as in animal models 17, 18 but not in all previous studies. 29 Recent studies have shown that genetic deficiency of apoC-III is associated with lower triglyceride levels and that antisense therapy to apoC-III decreases plasma triglyceride levels in humans confirming mechanistic significance. 30 ApoC-III is an inhibitor of LPL and also inhibits lipoprotein clearance by blocking the engagement of apoE and apoB to their receptors. 31 We observed that CsA did not increase apoC-III levels in wt mice, suggesting that the CsA-induced increase in apoC-III levels requires impaired LDLr activity and presumably impaired lipoprotein clearance. It is unclear whether the extent to which LPL activity was inhibited by CsA is functionally important in this animal model because VLDL-triglyceride content and particle size were unchanged. In humans heterozygous for LRP1; E) , hepatic syndecan-1 (F), brain apoE receptor 2 (apoER2; G), and heart VLDL receptor (VLDLr; H) protein levels were determined by Western blotting. Protein levels were corrected for α-tubulin levels and Ctrl values were set at 1. Bar graph shown is mean±SEM (n=7-9). A representative Western blot for 4 to 5 mice is shown. *P<0.05. LPL deficiency, VLDL particle size was not affected, 32 implying that partial LPL deficiency does not necessarily affect VLDL particle size.
We also made the novel observation of increased levels of plasma PCSK9 in Ldlr −/− mice treated with CsA, with a striking correlation between blood CsA and PCSK9 levels. Elevated levels of PCSK9 in Ldlr −/− mice have been reported and are consistent with high circulating levels of PCSK9 in humans with LDLr deficiency. 22, 33 That CsA increases PCSK9 levels in the absence of functional LDLr is intriguing. Other potential PCSK9 targets such as the VLDL receptor, 24 low-density lipoprotein receptor-related protein 1, 25 apoE receptor 2, 24 or syndecan-1 levels were not affected by CsA, implying the presence of a yet unrecognized clearance pathways for PCSK9 which are modulated by CsA. The absence of any correlation between PCSK9 and LDL-C in vehicle-treated mice emphasizes the mechanistic link among CsA, elevation of PCSK9, and elevation of LDL levels. Interestingly, PCSK9 was predicted to be a direct binding partner for CsA in a human structural proteome-wide characterization of CsA targets. 34 Recently, induction of a gain-of-function mutant of PCSK9 increased VLDL-triglyceride and IDL/LDL levels in Ldlr −/− mice 35 and supports the possibility of elevated PCSK9 levels contributing to CsA-induced hyperlipidemia in our Ldlr −/− mice.
Blood CsA levels achieved in our study were 711±91 ng/ mL after 4 weeks of treatment which are slightly higher than levels achieved in humans (100-400 ng/mL) 36 but are consistent with other animal studies, which report CsA levels of ≈1300 ng/mL at administered dose of 50 mg/kg per d 37 and between 360 and 1066 ng/mL CsA at 20 mg/kg per d. 14, 38 Published literature indicates that blood CsA levels can correlate with plasma lipid levels 13, 39 and may be relevant to some of our findings.
Although previous animal studies of CsA-induced hyperlipidemia have provided contradictory mechanistic conclusions, several previous studies share the observation that the effects of CsA are more prominent under conditions which either interfere with normal lipid homeostasis or confer baseline hyperlipidemia. Matsumoto et al 13 found that CsA increased plasma lipid levels in hyperlipidemic apoE-knockout mice and Emeson et al 40 and Ragheb et al 41 reported a strong dyslipidemia in C57Bl/6 mice and New Zealand White rabbits treated with CsA only when they were fed a high-fat diet. Taken together with our own findings, it is likely that CsA perturbs multiple pathways relevant to lipoprotein metabolism and that the residual capacity of lipoprotein clearance pathways determines the final alterations in plasma lipoproteins after exposure to CsA. We interpret the LDLr as providing important capacity for lipoprotein clearance which compensates for the effects of CsA on other pathways. This has important clinical implications because it implies that simultaneously targeting both permissive pathways such as the LDLr (eg, with statins and PCSK9 inhibitors) and direct pathways (eg, LPL, PCSK9, apoC-III, with direct biological therapies) may mitigate CsA-induced hyperlipidemia in patients.
In conclusion, we have demonstrated that CsA does not cause hyperlipidemia via direct effects on the LDL receptor.
Rather, the absence of the LDLr plays an important permissive role for CsA-induced hyperlipidemia, which is related to abnormal lipoprotein clearance, LPL activity, and increased apoC-III and PCSK9. Enhancing LDLr and LPL activity and decreasing apoC-III and PCSK9 levels may provide attractive treatment targets for transplant patients receiving CsA.
